Holen Sie sich die Stockscreener-App
33.93
2.50%
-0.87
Handel nachbörslich:
34.02
0.09
+0.27%
Schlusskurs vom Vortag:
$34.80
Offen:
$34.5
24-Stunden-Volumen:
2.39M
Relative Volume:
0.81
Marktkapitalisierung:
$3.92B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-359.64M
KGV:
-10.66
EPS:
-3.1831
Netto-Cashflow:
$-278.69M
1W Leistung:
+13.40%
1M Leistung:
+2.88%
6M Leistung:
+5.11%
1J Leistung:
+50.00%
1-Tages-Spanne:
$33.77
$35.24
1-Wochen-Bereich:
$30.33
$35.24
52-Wochen-Spanne:
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.93 | 4.02B | 0 | -359.64M | -278.69M | -3.1831 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines - Yahoo Finance
Viking Therapeutics Inc (1VT.HM) Interactive Stock Chart - Yahoo! Finance Canada
Viking Therapeutics, Inc. (VKTX) latest stock news and headlines - Yahoo Finance Singapore
Viking Therapeutics, Inc. (VKTX) interactive stock chart - Yahoo Finance Singapore
Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history - Yahoo Finance Singapore
Where Will Viking Therapeutics Stock Be in 10 Years? - The Globe and Mail
Where Will Viking Therapeutics Stock Be in 10 Years? - The Motley Fool
Did VK2735’s VANQUISH-2 Enrollment Milestone Just Reframe Viking Therapeutics' (VKTX) Obesity Drug Ambitions? - Yahoo Finance
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - stocktwits.com
Viking Therapeutics (VKTX) stock has failed to impress since Jim Cramer expressed caution - MSN
VKTX Forecast, Price Target & Analyst Ratings | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
How (VKTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today - Sahm
[ARS] Viking Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Viking Therapeutics, Inc. Definitive Proxy Statement - stocktitan.net
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
43,152 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Royal Fund Management LLC - marketbeat.com
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program - Sahm
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
VKTX stock jumps as retail traders pile into obesity pipeline bets - MSN
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress - Sahm
Viking Therapeutics (VKTX) Stock Has Failed To Impress Since Jim Cramer Expressed Caution - Insider Monkey
Viking Therapeutics, Inc. (VKTX) Falls Further Than the Overall Market: What Investors Should Know - Bitget
Viking Therapeutics Approaches Make-or-Break Moment as Key GLP-1 Data Looms - NAI500
Viking Therapeutics moves closer to challenging Ozempic with phase 3 trial progress - MSN
Viking Therapeutics: A Small Biotech Firm Competing in the $100B GLP-1 MarketNews and Statistics - indexbox.io
1 Reason This Biotech Stock Could Triple Before Year-End - Yahoo Finance
VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets - stocktwits.com
A Look At Viking Therapeutics (VKTX) Valuation As VK2735 Phase 3 Enrollment Reaches Completion - Yahoo Finance
Viking Therapeutics Inc (VKTX) Stock Price, Quote, News & History - Benzinga
Viking Therapeutics Trial Milestone Highlights VK2735 And Valuation Gap - simplywall.st
Vanguard disaggregates holdings; reports 0 shares in Viking (VKTX) - Stock Titan
VKTX Completes Participant Recruitment for Second Advanced Clinical Trial of Obesity Medication - Bitget
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug - Yahoo Finance
Viking Therapeutics completes patient enrolment in VANQUISH-2 trial - Clinical Trials Arena
Viking Therapeutics completes enrollment in obesity drug trial By Investing.com - Investing.com Australia
Published on: 2026-03-27 10:35:11 - baoquankhu1.vn
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
VKTX.O - Reuters
Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research - MarketBeat
Morgan Stanley reiterates Viking Therapeutics stock rating on trial progress - Investing.com
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Viking Therapeutics (VKTX) Completes Enrollment for Key Clinical Trials - GuruFocus
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):